MA-ULTIVUE/INDIVUMED
18.11.2020 15:19:08 CET | Business Wire | Press release
Ultivue and Indivumed today announced that the two companies have entered into a collaborative partnership to further accelerate research and drug development in the area of personalized oncology.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201118005281/en/
The deal links Indivumed’s vast array of standardized and fully comparable tissue biospecimens and analytical experience in IHC technology with Ultivue’s InSituPlex platform for high-throughput multiplex immunofluorescence. Ultivue’s standardized assay development for whole tissue phenotyping, when combined with Indivumed’s multi-omics oncology tissue biobank and capabilities to perform IHC multiplex assays, will enable deeper insights into tumor biology, unveiling complex mechanisms of cancer.
“By bringing Ultivue’s technology and expertise into our workflow, we’re giving our customers access to the contextual profiling of key cellular phenotypes,” says Prof. Dr. Hartmut Juhl, founder and CEO of Indivumed. “The data that can now be extracted from these valuable assets in our repository can support the full characterization of samples for biomarker and target discovery, drug development, clinical trials, and individualized therapy research. It will complete our offer in combination with the existing broad menu of IHC assays and end-to-end service”
Cambridge-based UItivue’s InSituPlex multiplexing technology is designed for fast and comprehensive exploration of biologically-relevant markers in tissue samples.
“InSituPlex is built to derive more biologically-relevant data from patient tissue samples at scale,” notes Jacques Corriveau, President and CEO of Ultivue. “By providing Indivumed with this capability and complementing its extensive biospecimen resources, we can enable researchers to rapidly assess the clinical utility of tissue biomarkers to increase the success of clinical trials in the I/O space.”
About Indivumed:
Indivumed is a physician-led, integrated global oncology company committed to unveiling complex mechanisms of cancer, in order to support precision oncology. Only a multi-omics approach can achieve this goal – and reliable multi-omics require especially high-quality biospecimens and data. Through its three divisions, IndivuServ, IndivuType, and IndivuTest, Indivumed offers specialized products and services that support customers in biomarker and target discovery, drug development, clinical trials, individualized therapy and more.
Indivumed is headquartered in Hamburg, Germany, with a US-based subsidiary and a global clinical network.
About Ultivue:
Ultivue provides researchers and scientists with multiplex biomarker assays for tissue phenotyping and digital pathology. Its proprietary InSituPlex technology enables advanced exploration and interrogation of tissue samples for precision medicine research. These highly customizable solutions and Ultivue’s scientific consultative approach strengthen and accelerate biomarker discovery and drug development programs.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201118005281/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Sihoo præsenterer næste generation af ergonomiske kontorløsninger på ORGATEC 202620.10.2026 20:12:00 CEST | Pressemeddelelse
Med ORGATEC 2026 lige om hjørnet vil Sihoo, specialist i ergonomiske sidde løsninger, præsentere sine næste generations løsninger til arbejdspladsen i hal 8.1, stand A-060 og B-061. I tråd med messens tema, »Fra rum til relationer: design af rum i en verden i konstant forandring«, vil Sihoo demonstrere, hvordan adaptivt ergonomisk design understøtter skiftende siddestillinger og nye behov på moderne arbejdspladser. Der er multimedier i denne pressemeddelelse. Se hele meddelelsen her: https://www.businesswire.com/news/home/20261020048673/da/ Sihoo på ORGATEC 2026 i Köln En oplevelseszone baseret på forskellige arbejdsscenarier Sihoos stand har et åbent layout, hvor en orange-hvid farvepalet kombineres med loftskonstruktioner i flere niveauer, halvgennemsigtige skillevægge og integreret belysning. Arbejdsstationer med højdejusterbare skriveborde og skærme samt siddeområder til samarbejde genskaber velkendte kontormiljøer og viser, hvordan ergonomiske stole passer ind på moderne arbejdspl
FPT and the Niels Bohr Institute Advance Vietnam–Denmark Collaboration in Quantum Talent Development20.10.2026 20:07:00 CEST | Press release
In the presence of H.E. Tô Lâm, General Secretary of the Communist Party of Vietnam and President of Vietnam, and His Majesty King Frederik X of Denmark, FPT Corporation, Vietnam's leading technology corporation operating in 31 countries and territories, and the Niels Bohr Institute (NBI), University of Copenhagen, one of the world's leading quantum research institutions, exchanged a Memorandum of Understanding (MoU) to strengthen collaboration in quantum science and technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261019899787/en/ General Secretary of the Communist Party of Vietnam Central Committee and President To Lam, Danish King Frederik X and delegates at the Vietnam–Denmark Business Forum in Copenhagen on October 20. (Photo: VNA) The partnership aims to strengthen scientific cooperation between Vietnam and Denmark by connecting Vietnamese researchers with one of the world's foremost centers for quantum resea
Grafana Labs Charts the Path to Agentic Operations with Watchers, Pages, and Agent Observability at ObservabilityCON 202620.10.2026 19:00:00 CEST | Press release
Grafana Labs delivers AI for observability and observability for AI: always-on agents to operate systems, and OpenTelemetry-native visibility into the agents you ship Grafana Labs, the company behind the open agentic observability cloud, today announced new releases at ObservabilityCON 2026 that move Grafana Cloud towards agentic operations, including the general availability of Agent Observability with OpenTelemetry support and of Assistant Watchers, and previews of Grafana Pages and Grafana Managed Sandboxes. As AI moves into production, teams face two connected challenges: using agents to operate their systems and understanding the behavior of the agents themselves. In the 2026 State of Observability Report, also released this week by Grafana Labs and ETR, a Futurum company, 68% of the 300 IT and engineering leaders surveyed have moved AI for observability past investigation into pilots or production. But confidence depends on the task and readiness varies: 85% report comfort with r
Grafana Labs Brings Faster Full-text Search and Smarter Data Optimization to Grafana Cloud at ObservabilityCON 202620.10.2026 19:00:00 CEST | Press release
Adaptive Logs Archive lets teams keep more logs for less, and faster queries for rare values in Grafana Cloud Logs help them, and their agents, find what matters in seconds Grafana Labs, the company behind the open agentic observability cloud, today announced new releases at ObservabilityCON 2026 that help teams manage their telemetry in the AI era, finding the right log line in seconds and keeping only the telemetry worth paying for as AI workloads scale. Major query performance enhancements to Grafana Cloud Logs, built on technology from the company's Logline acquisition, are now generally available, and Adaptive Logs Archive is in public preview. AI is massively increasing telemetry volumes. Coding agents are turning everyone into a developer, so more software is being built, faster, and all of it needs to be watched. The agents add to the load too, since every agent call and tool call emits its own telemetry. Left alone, observability costs grow with every new workload, which makes
Nissan Technical Centre Europe Adopts Sonatus Fastlane™ Platform to Accelerate Vehicle Test and Validation20.10.2026 18:37:00 CEST | Press release
Event-driven data collection and AI-powered root-cause analysis to become standard practice for new NTCE vehicle programs; Proven to cut investigation time from two weeks to two days Following a successful proof of concept and ongoing engineering development over the past 12 months, Nissan Technical Centre Europe (NTCE), Nissan’s primary R&D hub for its global regions, is expanding its use of the Sonatus® Fastlane™ Platform across its pre-start-of-production (SOP) validation workflow. The platform’s event-driven data collection and root-cause analysis have reduced the time NTCE engineers spend investigating vehicle software issues from two weeks to two days. NTCE plans to make the platform a standard part of validating future vehicle programs, including upcoming models such as the Nissan JUKE. With the Fastlane Platform, engineers have the data they need from the moment a fault occurs. Teams deploy targeted data-collection policies from the cloud, and capture begins automatically when
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom